BioAge Labs, Inc. $BIOA Shares Sold by Bank of America Corp DE

Bank of America Corp DE lowered its stake in shares of BioAge Labs, Inc. (NASDAQ:BIOA - Free Report) by 67.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,508 shares of the company's stock after selling 127,175 shares during the period. Bank of America Corp DE owned about 0.14% of BioAge Labs worth $1,076,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of BIOA. Janus Henderson Group PLC boosted its holdings in BioAge Labs by 411.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock worth $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of BioAge Labs during the fourth quarter valued at approximately $13,892,000. Stempoint Capital LP purchased a new position in shares of BioAge Labs in the first quarter valued at approximately $5,923,000. Millennium Management LLC lifted its position in shares of BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company's stock valued at $1,803,000 after acquiring an additional 270,479 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in shares of BioAge Labs in the fourth quarter worth approximately $3,215,000.

Analysts Set New Price Targets

Several research firms recently commented on BIOA. Needham & Company LLC reduced their price objective on BioAge Labs from $50.00 to $35.00 and set a "buy" rating for the company in a research note on Friday, July 31st. BTIG Research reaffirmed a "buy" rating and set a $40.00 target price on shares of BioAge Labs in a report on Monday, August 3rd. Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a research report on Friday, July 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Finally, Roth Capital restated a "buy" rating and set a $25.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.57.

BioAge Labs Stock Up 0.9%

Shares of NASDAQ:BIOA opened at $9.59 on Friday. The business has a fifty day moving average of $16.50 and a two-hundred day moving average of $17.82. The stock has a market cap of $440.18 million, a P/E ratio of -4.03 and a beta of 0.94. BioAge Labs, Inc. has a 52-week low of $4.58 and a 52-week high of $25.95.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The business had revenue of $2.45 million during the quarter. On average, equities analysts anticipate that BioAge Labs, Inc. will post -2.45 earnings per share for the current year.

BioAge Labs Profile

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source